Standardization of a Platform of Preclinical Models Derived From NSCLC Patients

Recruiting now

Conditions studied: Non-Small Cell Lung Cancer

In brief

Characterize and trace innovative nutraceuticals based on microencapsulated resveratrol and Cynara cardunculus extract, using preclinical models such as organotypic tissue slices and tumoroids created from tumor fragments derived from patients with non-small cell lung cancer. This will enable the development of combination therapies to increase the efficacy of immunotherapy in NSCLC and reduce side effects that lead to treatment discontinuation. The market implementation of these products may offer unique advantages, including increased clinical efficacy, improved tolerability of immune checkpoint inhibitors, reduced healthcare costs, improved quality of life for patients and their families, traceability of naturally derived products, and environmental sustainability.

Key facts

Study ID

NCT07629375

Run by

Regina Elena Cancer Institute

People needed

5

Starts

2025-07-24

Expected to finish

2026-07-24

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients over 18 years of age;
• Patients diagnosed with resectable NSCLC who will undergo curative surgery;
• Patients who give written informed consent (study participation and data processing).

You may not qualify if…

• Previous malignancies;
• Previous systemic treatments.

Where it is running

• IRCCS National Cancer Institute "Regina Elena" — Rome, Rome, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.